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Intramuscular (IM) ziprasidone has been associated with QTc interval prolongations in patients with preexisting risk factors. A 23-
year-old male Chinese schizophrenia patient experienced an increase of QTc interval of 83 milliseconds (ms) after receiving 20mg
IM ziprasidone (baseline and increased QT/QTc were, respectively, 384/418 and 450/501). This was rated as a probable adverse
drug reaction (ADR) by the Liverpool ADR causality assessment tool. A systematic review including all types of trials reporting the
effect of IM ziprasidone on the QTc interval prolongation identified 19 trials with a total of 1428 patients. Mean QTc change from
baseline to end of each study was −3.7 to 12.8ms after IM ziprasidone. Four randomized trials (3 of 4 published in Chinese) were
used to calculate a meta-analysis of QTc interval prolongation which showed no significant differences between IM ziprasidone
and IM haloperidol groups (risk ratio 0.49 to 4.31, 95% confidence interval 0.09 to 19.68, P = 0.06 to 0.41). However, our review
included two cases of patients who experienced symptoms probably related to QTc prolongation after IM ziprasidone.Thus, careful
screening and close monitoring, including baseline ECG, should be considered in patients receiving IM ziprasidone for the first
time.
1. Introduction
The second-generation antipsychotic ziprasidone is available
for intramuscular (IM) use in the management of acute
agitation associated with schizophrenia [1]. IM ziprasidone
is described as potentially causing QT interval prolongation
in large doses or in patients with other risks for interval
prolongation [2].Other antipsychotics, such as sertindole and
thioridazine, prolong the QT interval and are associated with
cases of torsades de pointes and sudden death [3].The clinical
significance of QTc prolongation induced by ziprasidone
administration is unclear [4]. In fact, reports of cardiac
adverse drug reactions (ADRs) that are clearly associatedwith
ziprasidone remain scarce [5]. A recent pharmacoepidemi-
ology study suggested that ziprasidone and amisulpride had
potential torsadogenic risk similar to haloperidol [6].
In China, IM ziprasidone is the first and only atypical
antipsychotic agent in clinical use for agitation associated
with schizophrenia. Although previous studies have demon-
strated that IM ziprasidone is well-tolerated for treatment of
agitation in schizophrenia in Western populations [1], clini-
cians now recognize that racial differences may contribute to
altered tolerability [7]. The data on efficacy and safety of IM
ziprasidone for agitation are still scarce in China, especially
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the effect of IM ziprasidone on QTc interval [7]. Here we
present a Chinese patient with no known risk factors who
experienced a prolongedQT interval after receiving amodest
dose of IM ziprasidone.
2. Case Presentation
Mr. A, a 23-year-old Chinese male, was brought in by his
family to the emergency department (ED) with acute psy-
chotic symptoms including disorganized speech, delusion,
and agitation. There was no history of substance abuse. A
provisional diagnosis of schizophrenia was made. He had
never taken antipsychotics and had no preexisting cardio-
vascular conditions and no known medical illness. Physical
examination was unremarkable. His weight was 68 kg and his
body mass index (BMI) was 22.2. The basic metabolic panel
values, including serumpotassiumand glucose levels, were all
within normal limits. Serum magnesium was not measured
but he had no clinical condition associated with hypo-
magnesemia. Although psychotic symptoms were prominent
at admission, his vital signs remained relatively stable at
arrival: blood pressure (BP): 100/70mmHg; pulse: 76 beats
per minute (bpm); respiration rate: 18 respirations/minute;
and temperature 36.0∘C.Abaseline electrocardiogram (ECG)
was obtained which showed normal sinus rhythm and a
QT/QTc of 384/418 milliseconds (ms) at a pulse of 78 bpm.
During the ED stay, an initial IM ziprasidone dose of
10mg was given and then IM doses of 10mg with oral
oxazepam of 30mg were prescribed every 6 hours as needed
for agitation. The total IM ziprasidone dose was 20mg. An
ECGobtained 24 hours later showed aQT/QTc of 450/501ms
with a pulse rate of 94 bpm.The increased QTc from baseline
was 83ms, a significant prolongation, but no symptoms
occurred. Ziprasidone was then switched to oral olanzapine
5mg/day, with oxazepam 30mg/day. His QT/QTc returned
to 366/416ms at a pulse of 93 bpm 48 hours after the last
ziprasidone injection. The QT/QTc returned to 382/402ms
72 hours after the last dose of ziprasidone.This QTc of 402ms
is 16ms lower than at baseline and 99ms lower than during
ziprasidone treatment. The patient was later transferred to
inpatient services for further treatment.
All authors agreed that this was a probable ADR, accord-
ing to the Liverpool ADR causality assessment tool [8].
Therefore, this case demonstrated a significantly prolonged
QT/QTc interval after modest doses of ziprasidone.
3. Discussion
3.1. Comprehensive Literature Review and Meta-Analysis. A
systematic review on this topic was conducted. Our protocol
of reviewing IM ziprasidone for acute psychosis has been
published online (http://www.crd.york.ac.uk/prospero/).The
registration number was CRD42014007542 at the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA), which provides an evidence-based minimum
set of items for reporting in systematic reviews and meta-
analyses.
All types of trials that included the effect of IM ziprasi-
done on the QTc interval prolongation were eligible for
inclusion. We included case series, retrospective studies,
open-label prospective trials, and randomized controlled
trials (RCTs). We excluded meta-analyses and systematic
reviews. We searched the PubMed, Embase, and Cochrane
Library databases. We also searched the Chinese databases
(CBM and CNKI databases) using the same key words. The
search included all studies published between January 2000
and December 2012, regardless of language. The keywords
used for the searches included schizophrenia, intramuscular
ziprasidone, QTc, and agitation. The keywords were used
in combination with the Boolean operators AND, OR, and
NOT. We used the “related article” function to supplement
the research. We also manually searched bibliographies of
RCTs, meta-analyses, case reports, and systematic reviews for
studies that were missed in the initial electronic search.
Review authors X-BL and WZ considered all included
studies initially, without seeing comparison data, to judge
clinical, methodological, and statistical heterogeneity, which
provided the basis for deciding whether each study would
be included for meta-analysis or other data synthesis. Data
from all included studies was extracted and organized into
standard, simple forms. In addition, to ensure reliability, X-
BL independently extracted data from a random sample of
these studies, comprising 30% of the total. Data presented
only in graphs and figures was extracted whenever possible
but was included only if two authors independently had the
same result. We also attempted to contact authors through an
open-ended request in order to obtain missing information
or for clarification whenever deemed necessary.
The meta-analysis was performed according to the rec-
ommendations of the Cochrane Collaboration, using the
Review Manager Version 5.1.7.0 software. Two authors (X-
BL and WZ) independently extracted data for analysis. We
presented the summary statistic of dichotomous outcomes as
a risk ratio for QTc interval prolongation ≥ 450ms, 450ms ≤
QTc interval < 480ms, and QTc interval ≥ 480ms. The
Mantel-Haenszel method was used to combine the summary
statistic. We used I2 methods to assess statistical heterogene-
ity. We used a fixed effect model if no heterogeneity existed
or I2 < 50% [24]. All statistical differences were considered
significant when 𝑃 < 0.05.
The search yielded 132 articles, 71 records remained
after duplicates were removed, 46 full-text publications were
assessed for eligibility, and finally 19 articles were included
in qualitative synthesis (Figure 1). The decision to include a
study or not in the meta-analysis was based on judgments
about clinical and methodological issues, and statistical
heterogeneity; 4 studies were included in the quantitative
synthesis. In total, 1428 patients had received IM ziprasidone
treatment and 836 patients had received IM haloperidol
treatment for agitation. The 19 reports included 12 RCTs
(ziprasidone versus haloperidol) [1, 7, 9–12, 14–16, 19, 22,
25], 5 open-label perspective trials [13, 17, 18, 20, 21], and
2 individual case reports [2, 4]. After multiple discussions
among the authors, it became clear that one trial had two
studies [18] but one of themwas also reported in a later larger
study [19]; therefore, one of these two studies was excluded
from Table 1, which summarizes the characteristics of the
included 19 studies. In only one of the studies [7] was it
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Records identified through
database searching (n = 129)
Additional records identified
through other sources (n = 3)
Records after duplicates removed (n = 71)
Records screened (n = 71)
Records excluded (n = 25)
Full-text articles assessed for eligibility (n = 46)
Full-text articles excluded (n = 27)
Review (n = 7)
Oral ziprasidone (10)
Others (n = 10)
Studies included in qualitative synthesis (n = 19)
Case report (n = 2)
Open-label trials (n = 5)
Randomized controlled trials (n = 12)
Studies included in quantitative synthesis (n = 4)
Figure 1: PRISMA flow diagram.
possible to estimate the effect size of the mean difference (see
Table 1, footnote 5) using Cohen’s method [23]. Four studies
[7, 16, 19, 22] with 288 patients, including three published in
the Chinese language [7, 16, 22], were included in our meta-
analysis (Figure 2).
In summary, in the IM ziprasidone group, only three
subjects (0.2%) had aQTc≥ 500ms; 3 subjects (0.2%) reached
a QTc ≥ 480ms; 10 (0.7%) had a QTc ≥ 450ms. On the other
hand, within the haloperidol group, one subject had a QTc ≥
500ms, 3 reached a QTc ≥ 480ms, and 3 had a QTc ≥ 450ms.
Seven patients (0.4%) of the IM ZPD group had QTc changes
that exceeded 60ms relative to the time-matched baseline
values. By combining all the studies included in Table 1, the
mean change in QTc from baseline to end of study was −3.7
to 12.8ms in the ziprasidone group; the corresponding QTc
change in the haloperidol group was −3.5 to 14.7ms.
Overall, IM ziprasidone had a mild effect on the QTc
interval prolongation. First, ziprasidone was associated with
modest concentration-related QTc increases [20]. Second, an
open-label perspective trial showed similar results including
(a) one with only 3 subjects having >60ms prolonged QTc
interval [17] and (b) another [13] indicating that IM ziprasi-
done did not appear to influence atrial and ventricular elec-
trical conduction in drug-free inpatients with schizophrenia.
However, the diagnosis of schizophrenia might influence
atrial conduction and even be associated with atrial fibrilla-
tion. Third, the ziprasidone versus haloperidol RCTs showed
that both agents were generally well tolerated; few subjects
experienced significant QTc interval prolongation in the
ziprasidone group (Table 1).
We paid particular attention to cardiac ADRs that may be
linked to IM ziprasidone. In the prospective trials and RCTs,
no patients reported symptoms related to QTc prolongation.
Two cases from other studies did have symptoms associated
with prolonged QTc interval. One patient lost consciousness
within 45min of IM ziprasidone injection of 20mg; she was
pulseless and hypotensive and her physical examination was
remarkable for absent pulses and signs of poor perfusion [4].
ECGmonitoring demonstrated bradycardia (30–40 beats per
minute) with a third-degree heart block. She had sponta-
neously converted to a normal sinus rhythm after a 36-hour
rescue including cardiopulmonary resuscitation. After using
an ADR scale the authors [4] concluded it was a probable
ziprasidone-induced ADR since the patient was not taking
any other medication and it was not an obvious heart-related
illness but, as the patient was 70 years old with dementia
and hypertension, they acknowledge that other unknown
medical conditions or risks might have also contributed. The
other subject was a 47-year-old male who admitted using
crack cocaine 72 hours before the presentation. He had
palpitations and weakness 45 minutes after receiving ziprasi-
done 20mg IM [2]. His maximum QT/QTc interval was
612/517milliseconds. Sanaei-Zadeh [26], commenting on this
case, emphasized that the baseline ECG before administering
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Figure 2: Meta-analysis comparing QTc in patients with intramuscular ziprasidone versus haloperidol.
ziprasidonewas already prolongedwith aQT/QTc of 484/475
milliseconds at a pulse of 58 beats per minute.
A meta-analysis of QTc interval prolongation ≥ 450ms,
450ms ≤ QTc interval < 480ms, and QTc interval ≥ 480ms
showed no significant differences in the IM ZPD group
compared with the haloperidol group, as demonstrated by
the Mantel-Haenszel fixed risk ratio, 0.49 to 4.31 (95%
confidence interval 0.09 to 19.68; I2 = 0%, 𝑃 = 0.06 to 0.41)
(Figure 2).
3.2. Case Discussion. This patient, a young, healthy male
with no preexisting cardiac conditions, received only the
recommended dose of IM ziprasidone for acute agitation
(20mg IM). The only concurrent use of medication was
oxazepam, which has no known effects on the QT interval
[27]. However, the change in QTc from baseline was 83ms,
and his maximum QT/QTc interval was 450/501ms.
While QT/QTc prolongation has been reported in
patients receiving IM ziprasidone, the extent of prolon-
gation in this patient is perhaps among the greatest in
China, especially considering that this occurred in a young,
healthy patient with no known preexisting conditions. Some
unknown factors, including genetic defects at the heart
potassium ion channel, may have played a role [28, 29].
Ziprasidone is only partly metabolized by CYP3A4 [30];
therefore, no known pharmacokinetic gene abnormalities are
expected to play a role in this case.
Our subsequent systematic review found that, among
1428 patients, only three subjects (0.2%) had a QTc ≥ 500ms.
In our calculations, the mean change in QTc from baseline
to end of study was −3.7 to 12.8ms after the ziprasidone
injection. This is comparable to other less comprehensive
reviews such as the one completed by Camm et al. [31]. Our
systematic review, including all IM trials, foundmore patients
who experienced QTc ≥ 480ms (3/1440 versus 1/4306) than
did the study by Camm et al. (which primarily focused on
oral ziprasidone). The greater IM versus oral effects may
be explained by higher peak serum concentrations in IM
administration [4].
Furthermore, meta-analysis of QTc interval prolongation
of four RCTs, including three only published in Chinese,
showedno significant differences in the IMziprasidone group
compared with the haloperidol group. However, similarity
to haloperidol does not guarantee safety, as the US IM
haloperidol prescribing information has a warning about
torsades de pointes [32].
Changes from baseline QTc interval were clinically mod-
est with both drugs, which is comparable to an important
RCT which showed that both ziprasidone and haloperidol
were generally well tolerated [19]. In general, these data are
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consistent with results from ziprasidone clinical pharmacol-
ogy studies and other reviews focused on QTc prolongation.
Taken together, they provide the most comprehensive evi-
dence published to date that IM ziprasidone appears to be
relatively safe for agitation.
Although several patients experienced significant QTc
interval prolongation in the current review, no cardiac ADRs
were reported in the prospective trials and RCTs. Neverthe-
less, our review found two cases [2, 11]; both had reported
symptoms related to QTc prolongation.
Most reported cases of prolonged QT interval associated
with ziprasidone use have occurred in patients with preex-
isting cardiovascular conditions, hypokalemia, hypomagne-
semia, concurrent use of other QT prolonging medications,
higher doses of ziprasidone (>40mg IM), rapid titration of
the dosage, or repeated dosing [2, 12]. Fortunately, most
patients experienced no symptoms associated with the QT
interval prolongation.
Most cases of drug-induced torsades de pointes occur in
the context of substantial prolongation of the QTc interval,
typically to values >500ms, but QTc alone is a relatively poor
predictor of arrhythmic risk in any individual patient. Some
drugs that substantially prolong the QTc interval produce
very low rates of torsades de pointes while others have much
smaller QTc effects but are considerably more proarrhythmic
[30].
3.3. Limitations. Although all authors agreed that this was
a probable ziprasidone-induced ADR, there is no absolute
proof that it was. One could argue that the QTc prolongation
was an artifact, but this conclusion does not appear likely
since the patient had 3 ECGs using the same equipment
and no other patient at that time showed similar QTc
prolongations.
Significant heterogeneity of the results in QTc ≥ 480ms
was seen in this meta-analysis, suggesting the effect of rele-
vant moderator and mediator variables. This may be because
meta- analyses combine results from trials that differ in their
methodology, sample size and year, patient and treatment
selection, and outcome variables. This meta-analysis only
included 288 patients from four RCTs because these were
the only ones identified in our search. The sample size was
relatively small for meta-analysis, which prevented further
data exploration. However, we included well-defined RCTs
comparing ziprasidone with haloperidol. Although there
were about 12 published RCTs, only 4 trials were included in
this meta-analysis after a more strict quality assessment.
4. Conclusion
As the first and only IM atypical antipsychotic medication
available in China, IM ziprasidone offers some advantages
over haloperidol [7, 9], which remains the most commonly
used medication for agitation in China [7]. Our case report
contributes to the current literature on ziprasidone use in
the Chinese population and indicates that, even in healthy
patients with no preexisting conditions, a modest dose of IM
ziprasidone can also cause significant prolonged QT interval.
In light of reports that a prolonged QTc interval may be
associated with torsades de pointes and sudden death [6],
a careful screening and close monitoring including regular
ECG should be considered. We were fortunate enough to get
a baseline ECG that demonstrated an increase inQTc interval
but we acknowledge that it is not always easy to get a baseline
ECG in an agitated psychotic patient.
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